AU2003277663A1 - Screening method - Google Patents

Screening method

Info

Publication number
AU2003277663A1
AU2003277663A1 AU2003277663A AU2003277663A AU2003277663A1 AU 2003277663 A1 AU2003277663 A1 AU 2003277663A1 AU 2003277663 A AU2003277663 A AU 2003277663A AU 2003277663 A AU2003277663 A AU 2003277663A AU 2003277663 A1 AU2003277663 A1 AU 2003277663A1
Authority
AU
Australia
Prior art keywords
screening method
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003277663A
Inventor
Ryo Fujii
Shuji Hinuma
Fumio Itoh
Yuji Kawamata
Hidetoshi Komatsu
Hiroshi Uejima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2003277663A1 publication Critical patent/AU2003277663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
AU2003277663A 2002-11-12 2003-11-11 Screening method Abandoned AU2003277663A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2002-328581 2002-11-12
JP2002328581 2002-11-12
JP2003-092033 2003-03-28
JP2003092033 2003-03-28
JP2003-168817 2003-06-13
JP2003168817 2003-06-13
PCT/JP2003/014292 WO2004043468A1 (en) 2002-11-12 2003-11-11 Screening method

Publications (1)

Publication Number Publication Date
AU2003277663A1 true AU2003277663A1 (en) 2004-06-03

Family

ID=32314785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003277663A Abandoned AU2003277663A1 (en) 2002-11-12 2003-11-11 Screening method

Country Status (2)

Country Link
AU (1) AU2003277663A1 (en)
WO (1) WO2004043468A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591120A4 (en) 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd Receptor agonists
WO2006070718A1 (en) * 2004-12-27 2006-07-06 Banyu Pharmaceutical Co., Ltd. Drugs for diseases accompanying changes in total bile acid pool or lipid metabolism disorders and method of screening these drugs
WO2010016552A1 (en) 2008-08-07 2010-02-11 武田薬品工業株式会社 Therapeutic agent for irritable bowel syndrome
WO2013102929A1 (en) 2011-12-26 2013-07-11 Cadila Healthcare Limited Novel compounds for treatment of diabetes, obesity or related disorders
WO2014100021A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
CN102993103B (en) * 2012-12-25 2015-07-29 湖南科技大学 N1, N3-dialkyl group replaces 3,4-dihydro-pyrimidin-2 ketone derivatives and preparation method thereof
US10493042B2 (en) 2013-08-01 2019-12-03 University-Industry Cooperation Group Of Kyung Hee University Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
WO2015016682A1 (en) 2013-08-01 2015-02-05 경희대학교 산학협력단 Pharmaceutical composition for preventing or treating diabetes mellitus, method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5
CA2954978A1 (en) * 2014-07-29 2016-02-04 Institut Pasteur De Lille 2-oxo-3,4-dihydropyridine-5-carboxylates and their use
WO2017134188A1 (en) * 2016-02-03 2017-08-10 Universite De Lille 2 Droit Et Sante Novel dihydropyridinone and dihydropyrimidinone compounds and their use
US20210346401A1 (en) * 2018-09-25 2021-11-11 Yichang Humanwell Pharmaceutical Co., Ltd Regulator of tgr5 signaling as immunomodulatory agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040669A1 (en) * 2000-11-17 2002-05-23 Banyu Pharmaceutical Co., Ltd. Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37
ATE394487T1 (en) * 2001-02-20 2008-05-15 Bayer Healthcare Ag HUMAN G-PROTEIN COUPLED RECEPTOR
EP1378749A4 (en) * 2001-04-12 2005-05-11 Takeda Pharmaceutical Screening method

Also Published As

Publication number Publication date
WO2004043468A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU2003296064A1 (en) Circular-cylinder sieve
AU2003277663A1 (en) Screening method
AU2003258070A1 (en) Electrodionization method
AU2002249467A1 (en) Screening method
AU2003242340A1 (en) Novel screening method
AU2003227268A1 (en) Novel screening method
AU2003285503A1 (en) Screening method
AU2003253813A1 (en) Method for colpoplasty
AU2003242342A1 (en) Novel screening method
AU2002952966A0 (en) Screening apparatus
AU2003202622A1 (en) A method of screening
AU2003217008A1 (en) Screening method
AU2002354247A1 (en) Screening method
AU2003278535A1 (en) Histoscreen method
AU2003248955A1 (en) Screening method
AU2003264722A1 (en) Methods
AU2003235310A1 (en) Novel screening method
AU2003303311A1 (en) Methods for selecting and screening for trasformants
AU2003210099A1 (en) New method
AU2003235120A1 (en) Screening method
AUPS286102A0 (en) Screening method
AU2003280725A1 (en) Screening method
AU2002952433A0 (en) Screening method
AU2002308887A1 (en) Regional bioimpedancemetry method
AU2002330455A1 (en) Screening method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase